CytoMed Therapeutics Past Earnings Performance
Past criteria checks 0/6
CytoMed Therapeutics's earnings have been declining at an average annual rate of -23.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 53% per year.
Key information
-23.8%
Earnings growth rate
-8.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 53.0% |
| Return on equity | -30.1% |
| Net Margin | -684.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How CytoMed Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -3 | 1 | 2 |
| 31 Mar 24 | 0 | -4 | 1 | 2 |
| 31 Dec 23 | 1 | -4 | 0 | 2 |
| 30 Sep 23 | 1 | -4 | 0 | 2 |
| 30 Jun 23 | 1 | -4 | 0 | 2 |
| 31 Mar 23 | 0 | -4 | 0 | 2 |
| 31 Dec 22 | 0 | -3 | 0 | 2 |
| 30 Sep 22 | 0 | -3 | 0 | 1 |
| 30 Jun 22 | 0 | -2 | 0 | 1 |
| 31 Mar 22 | 0 | -2 | 0 | 1 |
| 31 Dec 21 | 0 | -2 | 0 | 1 |
| 30 Sep 21 | 0 | -2 | 0 | 1 |
| 30 Jun 21 | 0 | -2 | 0 | 1 |
| 31 Mar 21 | 0 | -2 | 0 | 1 |
| 31 Dec 20 | 0 | -2 | 0 | 1 |
Quality Earnings: GDTC is currently unprofitable.
Growing Profit Margin: GDTC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GDTC is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.
Accelerating Growth: Unable to compare GDTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GDTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: GDTC has a negative Return on Equity (-30.15%), as it is currently unprofitable.